日本化学療法学会雑誌第56巻第3号
|
|
- しょうり いさやま
- 5 years ago
- Views:
Transcription
1 β Key words Candida albicans albicans Candida C. albicans Candida glabrata Candida krusei albicans Candida C. glabrata
2 C. albicans albicans Candida β in vitro in vivo C. glabrata C. krusei I β γ µ Candida
3 Table. Institutionstakingpartinthisstudy FirstDepartmentofSurgery,SapporoMedicalUniversityHospital DepartmentofSurgery,KeiyukaiSapporoHospital DepartmentofCriticalCareMedicine,IwateMedicalUniversityHospital DepartmentofGastroenterologicalandGeneralSurgery,YamagataUniversitySchoolofMedicine TohokuUniversityHospitalEmergencyCenter DepartmentofSurgery,TohokuKoseinenkinHospital DepartmentofChestSurgery,TohokuKoseinenkinHospital DepartmentofSurgery,AshikagaRedCrossHospital DepartmentofSurgery,NagaokaChuoGeneralHospital EmergencyandCriticalCareMedicine,SchoolofMedicine,KeioUniversity ThirdDepartmentofSurgery,TohoUniversityOhashiMedicalCenter DepartmentofSurgery,JikeiUniversitySchoolofMedicine DepartmentofSurgery,TeikyoUniversityHospital TraumaandCriticalCareCenter,TeikyoUniversitySchoolofMedicine ThirdDepartmentofSurgery,NihonUniversityItabashiHospital DepartmentofEmergency,NihonUniversityItabashiHospital EmergencyMedicalCenter,NipponMedicalSchoolTamaNagayamaHospital DepartmentofEmergency,TokyoMedicalUniversityHachiojiMedicalCenter DepartmentofSurgery,KitazatoUniversityHospital EmergencyCenter,KitazatoUniversityHospital GastroenterologicalCenter,YokohamaCityUniversityMedicalCenter AdvancedCriticalCareandEmergencyCenter,YokohamaCityUniversityMedicalCenter DepartmentofEmergencyandCriticalCareMedicine,SaiseikaiKanagawakenHospital DepartmentofSurgery,YokohamaMinamiKyosaiHospital DepartmentofEmergencyandCriticalCareMedicine,ChibaUniversityHospital DepartmentofSurgery,DokkyoMedicalUniversity,KoshigayaHospital DepartmentofTraumaandCriticalCareCenter,DokkyoMedicalUniversity,KoshigayaHospital DepartmentofEmergencyandIntensiveCareMedicine,TeikyoUniversitySchoolofMedicine,IchiharaHospital EmergencyandCriticalCareMedicine,KimitsuChuouHospital EmergencyandCriticalCareMedicine,NaritaRedCrossHospital DepartmentofEmergencyandCriticalCareMedicine,KamedaMedicalCenter IntensiveCareUnit,ChibaHokusohHospital,NipponMedicalSchool AnesthesiologyandMedicalCrisisManagement,NagoyaCityUniversityGraduateSchoolofMedicalSciences DepartmentofEmergencyandCriticalCareMedicine,FujitaHealthUniversitySchoolofMedicine DepartmentofEmergencyMedicine,SocialInsuranceChukyoHospital DepartmentofTransplantationandImmunology,GraduateSchoolofMedicineKyotoUniversity DepartmentofDigestiveSurgery,KyotoPrefecturalUniversityofMedicine DepartmentofSurgery,ShigaUniversityofMedicalScience DepartmentofThoracicSurgery,ShigaUniversityofMedicalScience DepartmentofEmergencyandCriticalCareMedicine,SchoolofMedicine,KanazawaUniversity DepartmentofSurgery,FukuiPrefectureSaiseikaiHospital SecondDepartmentofSurgery,ToyamaMedicalandPharmaceuticalUniversity DepartmentofTraumatologyandAcuteCriticalMedicine,OsakaUniversityGraduateSchoolofMedicine DepartmentofEmergencyandCriticalCareMedicine,KansaiMedicalUniversityHospital DepartmentofGastrointestinalSurgery,OsakaCityGeneralHospital DepartmentofSurgery,OsakaGeneralMedicalCenter CriticalCareandTraumaCenter,OsakaGeneralMedicalCenter NakakawachiMedicalCenterofAcuteMedicine IntensiveCareUnit,HyogoMedicalColegeHospital MedicalCenterforEmergencyandCriticalCare,NaraPrefecturalNaraHospital ThirdDepartmentofSurgery,JapaneseRedCrossSocietyWakayamaMedicalCenter KagawaUniversityHospitalEmergencyMedicalCenter DepartmentofSurgery,MatsuyamaShiminHospital DepartmentofGastroenterologicalSurgery,HiroshimaUniversityHospital DepartmentofEmergency,HiroshimaUniversityHospital DepartmentofAnesthesiologyandIntensiveCareMedicine,HiroshimaCityHospital DepartmentofEmergencyandCriticalCareMedicine,KurumeUniversityHospital DepartmentofEmergency,IizukaHospital DepartmentofSurgery,IizukaHospital DepartmentofNeurosurgery,IizukaHospital DepartmentofCardiovascularSurgery,IizukaHospital DepartmentofSurgery,SagaPrefecturalHospitalKoseikan DepartmentofAnesthesiology,KagoshimaMedicalAssociationHospital
4
5 Clinical Symptoms/Findings (Fungi Bacteria) Clinical Symptoms/Findings (Fungi alone) Marked improvement Marked improvement Improvement /Aggravation Bacterial tests Identification of causative bacteria Identified Not identified Not conducted Administration of antibacterial agent during MCFG Treatment Administered Not administered Results of bacterial cultures Eradicated Decreased Increased Improvement /Aggravation (a)akottalgorithm Step
6 From Step Clinical Symptoms/Findings (Fungi alone) Marked improvement Improvement Aggravation Results of fungal cultures Results of fungal cultures Eradicated Decreased Increased Eradicated Decreased Increased Imaging findings (X-ray, CT, etc.) Imaging findings (X-ray, CT, etc.) Imaging findings (X-ray, CT, etc.) Disappeared Improved Aggravated Disappeared Improved Aggravated Disappeared Improved Aggravated Disappeared Improved Aggravated Serological test values Serological test values Serological test values Normalized Decreased Increased Normalized Decreased Increased Normalized Decreased Increased Overall Clinical Effects of Antifungals Effective Ineffective (b)akottalgorithm Step Fig.. AKOTTalgorithm StepandStepforobjectivelyevaluatingantifungalagenteficacyinpatientswithbothfungalandbacterialinfections. Inordertoevaluatetheeficacyofantifungalagentsinpatientshavingbothbacterialandfungalinfections,atwo-stepalgorithm wascreated. IntheStep(a),theresultsofclinicaleficacyforbothbacterialandfungalinfectionarere-evaluatedbyconsideringthecausativebacteriaandtheirsensitivitytoantibacterialagentsgivenduringtheantifungaltherapy,andclinicaleficacyforfungalinfectionaloneisassessed. IntheStep(b),theresultsoftheclinicaleficacyforfungalinfectionalonefrom Step-arere-evaluatedbyconsideringtheresultsoffungalcultures,imagingfindings, andserologicaltestvalues,andoveralclinicaleficacyofantifungalagentsisobtained.
7 II C. albicans C. glabrata Candida tropicalis Candida parapsilosis C. krusei Aspergillus fumigatus Aspergillus niger
8 Patients enrolled and collected (n 8) Safety analysis (n 78) Efficacy analysis (n ) Removed from safety analysis (n ) Did not obtain information regarding the presence or absence of adverse effects (n ) Removed from efficacy analysis (n 66) Did not meet inclusion criteria (n 54) Received MCFG for less than 5 days (n 8) Provided too little information to determine effectiveness (n ) Fig.. Patientanalysisbreakdown. Table. Baselinedemographicsandpatientprofilesineficacyanalysis Baselineprofiles Sex Male Female Age(years) Mean±SD Range Underlyingdisease Surgeryofdigestiveorgans GItractperforation Cerebrovasculardisease(stroke) Burns Diabetesmelitus Trauma Pneumonia Post-livertransplantation Severeacutepancreatitis Others Field Surgery Emergency/Intensive-caremedicine Classificationofmycosis Proven Probable/Possible No.(%)ofpatients (n=) 69( 6. 6) 43( 38. 4) 6.6± ( 6. ) (. 7) (9. 8) (9. 8) 8(7. ) 8(7. ) 6(5. 4) 4(3. 6) 4(3. 6) 3( 6. 8) 7( 4. ) 85( 75. 9) 59( 5. 7) 53( 47. 3) C. albicans C. glabrata γ
9 AKOTT Algorithm Step Step Marked improvement (N 4) Improvement (N 44) (N 38) Aggravation (N 6) Marked improvement (N 3) (N 4) (N ) (N 43) Improvement (N 44) (N ) (N ) (N ) Aggravation (N ) (N ) (N ) (N ) Effective (N 7) (N 6) Ineffective (N 8) (N 4) (N ) Fig.3. ResultsofAKOTTalgorithm evaluation. Table3. Classificationofprovenfungalinfections Provenfungalinfection No.ofpatients(total= 59) Candidiasis 58 Candidemia 9 Pulmonarycandidiasis 7 Urinarycandidiasis Candidaperitonitis 7 Candidaabscess 3 Candidacholangitis Aspergilosis Invasivepulmonaryaspergilosis Fungiisolated No.ofstrains(total= 78) C.albicans 36 C.glabrata C.tropicalis 5 C.parapsilosis C.krusei Candidaspp,nonspecific 9 A.fumigatus A.niger Yeast-likefungus γ III
10 Table4. Overalclinicaleficacy Field Surgery Emergencyand intensive-caremedicine Total Efective Inefective Eficacy(%) 5 3 9/4 (79.) /76 (69.7) 8 7/ (7.) Table5. Eficacybydiagnosisoffungalinfections FungalInfection Proven Candidiasis Candidemia Pulmonarycandidiasis Urinarycandidiasis Candidaperitonitis Candidaabscess Candidacholangitis Aspergilosis Invasivepulmonaryaspergilosis Probable/Possible Total Eficacy(%) 44/57 (77. ) 44/56 (78. 6) 7/9 (77. 8) /6 (84. 6) 8/ (7. 7) 4/6 (66. 7) /3 (66. 7) / ( ) / (. ) / (. ) 8/43 (65. ) 7/ (7. ) Table8. Commondrug-relatedadversereactionsduringmicafungintherapy Adversereaction Abnormalhepaticfunction Elevatedγ-GTP ElevatedAl-p Elevatedbilirubin ElevatedALT Increasedplateletcount Mild No.ofepisodes Moderate Serious 3 Total Of78patientsevaluableforsafetyassessment,37sufered69 drug-relatedadversereactions. Table6. Eradicationoffungibymicafungintreatment Fungi C.albicans C.glabrata C.tropicalis C.parapsilosis C.krusei Candidaspp,nonspecific A.niger Yeast-likefungus Total Strainseradicated(%) 3/3 6/8 3/4 / / 7/9 / / 5/67 (74. ) (88. 9) (75. ) (. ) ( ) (77. 8) (. ) ( ) (77. 6) Table7. Eficacybymaximum dailymicafungindose Dose(mg) Efective Inefective Eficacy(%) Total / 5/3 ( 78. ) 5/7 3/3 ( 76. 7) 5/ ( 7. 4) 3/4 /5 7/( 7. )
11 C. albicans C. glabrata C. albicans C. glabrata C. krusei albicans C. albicans albicans C. albicans C. glabrata C. krusei C. albicans C. glabrata γ
12 β Candida Candida albicans Candida glabrata Candida albicans Aspergillus fumigatus β Candida albicans
13 Candida Aspergillus β
14 β
日本化学療法学会雑誌第54巻第S-1号
β β Key words β Candida krusei Candida glabrata β I β Drugadministration Baselinecharacteristics Clinicalsymptom Mycologicaltests Plasmadrugconcn Adverseevents Laboratorytests ) -leadecg Clinicalphotograph
More information日本化学療法学会雑誌第58巻第2号
Key words β Candida Table1. MCFGCPAstudygroup Investigator (representative) YoshitsuguMiyazaki NaoyukiMiyashita RyoichiAmitani KenjiOgawa AtsuyukiKurashima ToshiroKiguchi MichiakiMishima YuichiInoue HiroshiSaito
More information日本化学療法学会雑誌第55巻第S-1号
µ µ Key words Streptococcus pneu- moniae S. pneumoniae µ µ I γ H H C HN F F O N O CO H H C SO H H O Fig.. ChemicalstructureofGRNX. γ γ II Haemophilus influenzae Pseudomonas aeruginosa Streptococcus intermedius
More information日本化学療法学会雑誌第59巻第5号
Streptococcus pneumoniae Haemophilus influenzae Moraxella catarrhalis S. pneumoniae H. influenzae M. catarrhalis S. pneumoniae H. influenzae M. catarrhalis S. pneumoniae H. influenzae M. catarrhalis S.
More information日本化学療法学会雑誌第56巻第1号
β β β β β Streptococcus pneumoniaehaemophilus influenzaemoraxella catarrhalismycoplasma pneumoniaechlamydia pneumoniae β Key wordsβ mys nilc laci ngis Table. Assessmentschedule Parameters Patientcharacteristics
More information日本化学療法学会雑誌第57巻第6号
Streptococcus pneumoniae Haemophilus influenzae Moraxella catarrhalis S. pneumoniae S. pneumoniae β β H. influenzae S. pneumoniae H. influenzae M. catarrhalis Key words Otalgia Fever Item Crying,Iritation,
More information感染症学雑誌第80巻第6号
Candida Candida albicans Candida parapsilosis Candida glabrata Candida tropicalis C. albicans C. grabrata C. tropicalis µ Candida guilliermondii µc. parapsilosis µ Candida µcandida C. albicans µ µ µ µ
More informationVOL.42 S-1
CHEMOTHERAPY APR. 1994 VOL.42 S-1 CHEMOTHERAPY APR. 1994 Table 1. Criteria for evaluation of clinical efficacy by the Japanese Society of Oral and Maxillo-Facial Surgeons Grades of symptoms and numerical
More informationKey words : 7432-S, Oral cephem, Urinary tract infection Fig. 1. Chemical structure of 7432-S.
Key words : 7432-S, Oral cephem, Urinary tract infection Fig. 1. Chemical structure of 7432-S. Table 1. Clinical summary of acute uncomplicated cystitis patients treated with 7432-S UTI : Criteria by the
More information1.8.2 Page MIC () MIC 50 / MIC 90 µg/ml Candida albicans (54) / Candida glabrata (25) 0.25 / 0.5 Candida guilliermondii a) (2)
1.8.2 Page1 1.8.2 96% 2002 40 B 1 123 (1) in vitro 1) in vitro C. glabrata C. krusei 1 2 19951997 3 1999 2002 MIC MIC 2 1.8.2 Page2 1 19951997 MIC () MIC 50 / MIC 90 µg/ml Candida albicans (54) 0.016 /
More information日本化学療法学会雑誌第58巻第4号
Escherichia coli Enterococcus faecalisstreptococcus agalactiae Klebsiella pneumoniae Staphylococcus epidermidis E. colie. faecalispseudomonas aeruginosa K. pneumoniae S. agalactiae E. coli E. coli μ p
More informationFig. 1 Chemical structure of norfioxacin (AM-715)
Fig. 1 Chemical structure of norfioxacin (AM-715) Table 1 Serum and biliary concentration of norfloxacin (AM-715) Table 2 Protocol for clinical evaluation of norfloxacin (AM-715) in the treatment of biliary
More information50mg 75mg (1) H 3 C O OH HO H O O H OH SO H 3 Na H H N H 2 N NH OH H N O O H H O OH H 3 C H O O N H H H HO H NH CH 3 HN HO H OH O H OH H NH
3240 14 8 8 50mg 75mg 13 6 25 1-(1) H 3 C O OH HO H O O H OH SO H 3 Na H H N H 2 N NH OH H N O O H H O OH H 3 C H O O N H H H HO H NH CH 3 HN HO H OH O H OH H NH O N O C 56 H 70 N 9 NaO 23 S 1292.26 5-[(1S,2S)-2-
More informationCHEMOTHERAPY APRIL 1992 Table 2. Concentration of meropenem in human prostatic fluid Table 1. Background of 21 chronic complicated UTI cases * NB + BPH, NB + Kidney tumor, NB + Kidney tuberculosis Table
More informationVOL.35 S-2 CHEMOTHERAPY Table 1 Sex and age distribution Table 2 Applications of treatment with carumonam Table 3 Concentration of carumonam in human
CHEMOTHERAPY Fig. 1 Chemical structure of carumonam Disodium(+)-(Z)-CCE1-(2-amino-4-thiazoly1)-2-[[(2S, -(carbamoyloxymethyl)-4-oxo-1-sulfonato-3-azetidinyll -2-oxoethylidene] amino] oxy] acetate 3S)-2
More informationFig.2. Sensitivity distribution of clinical isolates of S. epidermidis (24 strains, 106 CFU/ml) Staphylococcus aureus Staphylococcus epider- midis Ent
Fig.2. Sensitivity distribution of clinical isolates of S. epidermidis (24 strains, 106 CFU/ml) Staphylococcus aureus Staphylococcus epider- midis Enterococcus faecalis Klebsiella pneumoniae, Morganella
More informationTHE JAPANESE JOURNAL OF ANTIBIOTICS 65 2 Apr non-albicans 4 non-albicans C. glabrata, C. parapsilosis, C. tropicalis, C. krusei 4 C. guil
Apr. 2012 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 2 111 13 B ACTIONs Bundle ACTIONs Bundle 2009 7 ACTIONs Bundle ACTIONs project Appropriate Candidal Treatment, Implementation Of Nonneutropenic strategies
More informationFig. 1 Chemical structure of TE-031 Code number: TE-031 Chemical name: (-) (3R, 4S, 5S, 6R, 7R, 9R, 11R, 12R, 13S, 14R)-4-[(2, 6-dideoxy-3-C-methyl-3-
Fig. 1 Chemical structure of TE-031 Code number: TE-031 Chemical name: (-) (3R, 4S, 5S, 6R, 7R, 9R, 11R, 12R, 13S, 14R)-4-[(2, 6-dideoxy-3-C-methyl-3-O-methyl-a-L-ribo-hexopyranosyl) oxy]-14-ethyl-12,
More informationTable 1 Patients with various renal function * Ccr, Creatinine clearance ml/min per 1. 48 m2 ** C.V.D., Cerebral vascular disease ; C.R F., Chronic renal failure ; H.D., Hemoclialysis ; D., Dialyzer ;
More informationVOL. 40 S- 1 Table 1. Susceptibility of methicillin-resistant Staphylococcus aureus to meropenem Table 2. Coagulase typing of methicillin-resistant St
CHEMOTHERAPY VOL. 40 S- 1 Table 1. Susceptibility of methicillin-resistant Staphylococcus aureus to meropenem Table 2. Coagulase typing of methicillin-resistant Staphylococcus aureus CHEMOTHERAPY Table
More information日本化学療法学会雑誌第54巻第1号
Chlamydophila pneumoniae Chlamydophila psittaci Mycoplasma pneumoniae Legionella pneumophila C. pneumoniae C. psittaci C. pneumoniae C. psittaci M. pneumoniae M. pneumoniae C. psittaci L. pneumophila C.
More information日本化学療法学会雑誌第65巻第4号
Mycoplasma pneumoniae M. pneumoniae M. pneumoniae M. pneumoniae M. pneumoniae M. pneumoniae Key words Mycoplasma pneumoniae Mycoplasma pneumoniae M. pneumoniae I M. pneumoniae M. pneumoniae M. pneumoniae
More informationCHEMOTHERAPY FEB Table 1. Activity of cefpirome and others against clinical isolates
VOL.39 S-1 CHEMOTHERAPY FEB. 1981 Table 1. Activity of cefpirome and others against clinical isolates VOL.39 S-1 CHEMOTHERAPY FEB. 1991 72 M, 55.5 kg 66 F, 53 kg Chronic bronchitis Bronchopneumonia Peak
More information便失禁に対する仙骨神経刺激療法 前向き多施設共同研究 第67巻06号0371頁
67 I 1 2 3 日本大腸肛門病会誌 年間 1-1 号 第 67 巻第 6 号 (%) 1 214 年 6 月 山名哲郎ほか 375 (%) 1 8 8 5. 66.7 6 66.7 66.7 4 6 4 56.3 56.3 18.8 6.3 18.8 23.8 4.5 Test period 4.8 1M 3M 6M Test period 1M 3M 6M (n = 22) (n = 16)
More informationKey words : candidemia, endotoxin, D-arabinitol, Candida antigen, serological examination
Key words : candidemia, endotoxin, D-arabinitol, Candida antigen, serological examination Fig. 1 The value of fungal index and D- arabinitol/creatinine. Fungal index was mesured by Endotoxin D and Endospecy
More informationFeb THE JAPANESE JOURNAL OF ANTIBIOTICS Tebipenem pivoxil 1 1, Meiji Seika 2 Meiji Seika G 3 Meiji Seika Tebipen
Feb. 2016 THE JAPANESE JOURNAL OF ANTIBIOTICS 69 1 53 53 Tebipenem pivoxil 1 1, 3 2 2 1 1 Meiji Seika 2 Meiji Seika G 3 Meiji Seika 2015 12 15 Tebipenem pivoxil 10% 2010 4 2013 3 3,547 3,540 3,540 3,331
More information日本化学療法学会雑誌第54巻第S-1号
β β β Key words β β I HP- -CD CHR RHC R R R R CHR R R R R RHC R R R CHR R R R RHC CHR R H CH CH Fig.. Structuralformulaofhydroxypropyl-β -cyclodextrin(hp-β -CD). CH n H β β β β Table-. Dosageandadministration(Singleadministrationstudy)
More informationFig. 1 Chemical structure of KW-1070
Fig. 1 Chemical structure of KW-1070 Fig. 2 Sensitivity distribution of clinical isolates Fig. 4 Sensitivity distribution of clinical isolates Fig. 3 Sensitivity distribution of clinical isolates Fig.
More information日歯雑誌(H28・8月号)別刷り/ポスターセッション とびら
α P. gingivalis P. gingivalis αsmatgf- VEGF-A α in vitro μ Porphyromonas gingivalis in vitro Porphyromonas gingivalis β β β JBiolChem. μ μ μ β Porphyromonas gingivalis in vitro μ α β α
More informationCHEMOTHERAPY Silver sulfadiazine (T 107) CHEMOTHERAPY Fig. 1 Item of patients Table 1 Criteria of bacteriological efficacy by the Committee xcellent: E Score of infection becomes to 0% at the end of medication.
More informationO1-1 O1-2 O1-3 O1-4 O1-5 O1-6
O1-1 O1-2 O1-3 O1-4 O1-5 O1-6 O1-7 O1-8 O1-9 O1-10 O1-11 O1-12 O1-13 O1-14 O1-15 O1-16 O1-17 O1-18 O1-19 O1-20 O1-21 O1-22 O1-23 O1-24 O1-25 O1-26 O1-27 O1-28 O1-29 O1-30 O1-31 O1-32 O1-33 O1-34 O1-35
More informationA A
3 A B C A A 2 5 1 62 A 1 1 2 63 3 1 A proven invasive fungal diseases 1 2 3 BAL 24 : Fusarium spp. 4 2 : Candida Trichosporon B probable invasive fungal diseases Cpossible invasive fungal diseases 5 1
More informationStaphylococcus sp. K.pneumoniae P.mirabilis C.freundii E. cloacae Serratia sp. P. aeruginosa ml, Enterococcus avium >100ƒÊg/ml
CHEMOTHERAPY SEPT. 1992 cefoperazone ceftazidime (CAZ), imipenem (IPM) Staphylococcus sp., Enterococcus (CPZ), faecalis, Escherichia coli, Klebsiella pneumoniae, Citrobacter freundii, Enterobacter cloacae,
More information日本化学療法学会雑誌第54巻第S-1号
Key words β β Table. CmaxandAUCinsingleintravenousinjectionstudy ITCZAdministration (mg) n Cmax(ng/mL) ITCZ OH-ITCZ AUC( )(ng hr/ml) ITCZ OH-ITCZ 5 7.7± 9.7 9.7±.,959.7±.9,78.± 557.,59.±.9.± 5. 5,8.7±
More informationFig. 1 Chemical structure of DL-8280
Fig. 1 Chemical structure of DL-8280 Fig. 2 Susceptibility of cl in ical isolates to DL4280 Fig. 5 Susceptibility of clinical isolates to DL-8280 Fig. 3 Susceptibility of clinical isolates to DL-8280 Fig.
More informationTable 1. Antibacterial spectrum SBT ABPC ABPC CPZ : sulbactamiampicillin : ampicillin : cefoperazone
Table 1. Antibacterial spectrum SBT ABPC ABPC CPZ : sulbactamiampicillin : ampicillin : cefoperazone (inoculum size= 106 CFU/ml) (Ĉ-lactamase producer : 2 strains) Fig. 1. Sensitivity distribution of
More informationb) Gram-negative bacteria Fig. 2 Sensitivity distribution of clinical isolates : E. coli Fig. 3 Sensitivity distribution of clinical isolates : Pseudomonas Fig. 1 Sensitivity distribution of clinical isolates
More informationCHEMOTHERAPY JUNE 1993 Table 1. Background of patients in pharmacokinetic study
CHEMOTHERAPY JUNE 1993 Table 1. Background of patients in pharmacokinetic study VOL. 41 S 1 Table 2. Levels (Đg/ml or Đg/g) of S-1006 in serum, bile, and tissue (gallbladder) after oral administration
More information8 The Bulletin of Meiji University of Integrative Medicine API II 61 ASO X 11 7 X-4 6 X m 5 X-2 4 X 3 9 X 11 7 API 0.84 ASO X 1 1 MR-angio
7-14 2010 1 1 1 2 1 1 1 2 Fontaine II ASO61 3 API ASO ASO ASO API API KKKKKKKKKK ASO Fontaine II API Received April 14, 2009; Accepted July 16, 2009 I arteriosclerosis obliterans: ASO ASO 50 70 1,2 Fontaine
More informationTable 1. Antibacterial activitiy of grepafloxacin and other antibiotics against clinical isolates
Table 1. Antibacterial activitiy of grepafloxacin and other antibiotics against clinical isolates Table 2-1. Summary of patients treated with grepafloxacin for respiratory infection 1) Out: outpatient,
More informationcoccus aureus Corynebacterium sp, Haemophilus parainfluenzae Klebsiella pneumoniae Pseudornonas aeruginosa Pseudomonas sp., Xanthomonas maltophilia, F
VOL.43 S-1 coccus aureus Corynebacterium sp, Haemophilus parainfluenzae Klebsiella pneumoniae Pseudornonas aeruginosa Pseudomonas sp., Xanthomonas maltophilia, Flavobacter- Table 1. Concentration of grepafloxacin
More informationOsamu NEMOTO, M.D. Clinical and Bacteriological Research of Sucrose/ Povidone-Iodine Ointment (U-PASTA kowa) for Pressure Sores and Skin Ulcers Osamu Nemoto Department of Dermatology,Tonan Hosptal
More information日本化学療法学会雑誌第60巻第4号
Streptococcus pneumoniae Haemophilus influenzae S. pneumoniae H. influenzae Key words β Streptococcus pneumoniae Haemophilus influenzae S. pneumoniae H. influenzae μ μ S. pneumoniae H. influenzae S. pneumoniae
More information名称未設定-1
Study on Clinical Factors Affecting the Fungal Culture Test - Relevance of Dry Mouth - Yoshiko YAMAMURA, Yukihiro MOMOTA, Hideyuki TAKANO, Koichi KANI, Katsumi MOTEGI, Fumihiro MATSUMOTO, Masayuki AZUMA
More information立命館21_松本先生.indd
2143-552010 1 2 () 1 2 3 456 78- Key Words 1 3 12007 2 3 508 19992008 1 23 4 43 2120107 4 2008 1992 2003 2005 1989 2008 4 2 2-1 10 4 4 6 5 4 5 2946 1 155 11 41 44 45 4 2-2 2003 1 21 2 1 3 4 5 6 7 3 2120107
More information立命館20_服部先生.indd
20 93-105 2010 2 () ' - 1 ( ) ( ' 2005) Key Words 2 1967 93 20 2010 1 94 1 ' 2002 2 2 1996 1996 1999 2 2 2 1993 1999 4 1 2 1985 1989 1986 1994 4 1 2 1 1 4 2 4 4 1 4 1966 4 10-1970 20 1993-1972 95 20 2010
More information1996 2000 2004 1984 2005 7150 000 9 500 9 4 13 10 95 11 11 12 20002004 9 70
14 2006 1 Key Words 2002 3 1 2 3 3 1 2 3 1969 1987 69 1996 2000 2004 1984 2005 7150 000 9 500 9 4 13 10 95 11 11 12 20002004 9 70 14 2006 1 15 71 72 1 22 6 32 9 200 6 3 1 2 2000 10 1 2003 10 2005 6 5 4
More information立命館16_坂下.indd
1669-792008 1 - ' 85- -108 ' Key words 1 2 2003 69 1620082 5 3 1990 1997 4 5 2001 1307 6 7 1 1 1 1996 100 2 1997 71 3 1998 71 4 1999 96 5 2000 95 6 2001 145 7 2002 191 8 2003 174 9 2004 120 10 2005 122
More information立命館人間科学研究No.10
1 77 5 Key words 1 23 3 11417 14310045 20022004 2 2003 20022005 20022004 2 10200511 3 2003 1152003 59 1995 3 32003 19932002 20032003 2005 20052005 4 1997 2000521986 2001 42001 3 1981 6 1 7 5 1000248 1632647
More information立命館21_川端先生.indd
21 119-132 2010 ( ) ' Key Words 119 21 2010 7 1962 2001 2001 2007 1982 1988 1997 2007 1997 1998 1863 1880 1 1998 1998 2001 1599 120 121 1599 1695 8 1695 1714 4 1714 1715 5 1715 100 1812 9 1812 1864 2001
More information立命館14_前田.indd
1499-1122007 1 ) ) ) ) ) (1) -- ) ) ) ) ) ) ( ) ) ' ) ) ) ) - 1) 2)' 3) Key words 19811994 1721 99 1420073 100 20012004 2005 2004 2002 33 34 10 1987 45 20002003 2002 1 1 2000 1 1 2001 2 200341 12004 2
More information立命館17_坂下.indd
1793-1052008 1 () -- -- - Key words 1 93 1720088 2 3 2003 15 1996 50 3040 2 3 4050 50 10 1980 1995 1950 1958 1968 1972 94 95 1987 4 4 70 3 3 1 2000 2001 4 1720088 96 2001 2003 2 1978 1990 1997 130 2 3
More information立命館人間科学研究No.10
49 00 7 Key words 980 995 50 0005 90 997 99 990 994 99 99 99990 99 996 988988 994 99 995 995 995 994 984 988 986 997 997 00 995 00 5 7 5 5 999 997 997 998 6 998 999 997 997 998 0040000 994 996 000 00 5
More information立命館19_椎原他.indd
191-132009 1 ( ) ' Key Words 1 11 12007 2007 200520062 201120062 7558 4009 1 1920098 2007 2 2000 028 2005 1999 12 1999 13 1968 2 3 '1992 2007 2001 20052001 1977 2005 2005 2007 21 21 22 461927 3 13 1920098
More information立命館人間科学研究No.10
61 10 1990 Key words 1 102005 11 62 2000 1 1920 10 1892 63 1 1 19 100 1914 100 1 1 20 1 2 102005 11 64 1946 21 4 1947 1949 1947 22 1 3 1956 1959 1958 2 1964 65 2 10 1975 7080 70 2 1 1987 1990 40 1989 1989
More information立命館19_徳田.indd
1991-1022009 1 2 () )--) 28 2827 1 2 Key Words 1 (1721 2000 20012001 20082009 91 1920098 92 20042004 2004 2001 12 2005 20082009 2005 3 1997 200820096 2007 2 20082009 93 20012001 12 2008 2009 19611966 1
More informationTitle 神経因性膀胱にともなう排尿障害に対する塩酸ブナゾシンの臨床効果 - 二重盲検比較試験による検討 - 小柳, 知彦 ; 富樫, 正樹 ; 丸, 彰夫 ; 折笠, 精一 ; 相馬, Author(s) 崎, 淳 ; 安田, 耕作 ; 阿曽, 佳郎 ; 本問, 之夫 ; 三宅, 弘厚生 ; 熊
Title 神経因性膀胱にともなう排尿障害に対する塩酸ブナゾシンの臨床効果 - 二重盲検比較試験による検討 - 小柳, 知彦 ; 富樫, 正樹 ; 丸, 彰夫 ; 折笠, 精一 ; 相馬, Author(s) 崎, 淳 ; 安田, 耕作 ; 阿曽, 佳郎 ; 本問, 之夫 ; 三宅, 弘厚生 ; 熊澤, 淨一 ; 武井, 実根雄 Citation 泌尿器科紀要 (1990), 36(10): 1233-1252
More informationKey words: yeast, Etest(R), microdilution method, MIC Table 1 MICs of quality control strains The data shown are the range of MIC performed in triplicate Table 2 Renge of MICs, MIC50s and MIC90s for 81
More information1 見出し1,12ポ,日本語ゴシック,英語Arial,段落後は6ポの設定です
8. Page1 8. B 1 5) 6) 2099 2370 50 400 mg 19 (1) 1) (a) 78.9% 30/38 4 3 35.7% 5/14 71.4% 10/1485.7% 12/142 1 83.3% 5/63 2 1 1 1 8. Page2 (b) 2099 1897 82.4% 1562/1897 2 84.0% 1298/1545 3 2 80.4% 472/58779.0%
More informationTable 1 Classification of female patients with vesical irritating symptom by their signs : Urinary pain with or without other vesical irritability. s
Table 1 Classification of female patients with vesical irritating symptom by their signs : Urinary pain with or without other vesical irritability. s Vesical irritability without urinary Pain. Pyuria 10/
More informationTable 1 Profiles of 28 patients with Legionella pneumonia in Japan, 1980-1990 a) Y Taguchi, personal communication b) M. Hayase, personal communicatio
Key words: Legionella pneumonia, culture-positive, Japanese patients Legionella (L. pneumophila (L. micdadei, L. bozemanii, Table 1 Profiles of 28 patients with Legionella pneumonia in Japan, 1980-1990
More informationVOL.42 NO.3 R= H: Itraconazole R=OH: Hydroxy-itraconazole (R 63373) Fig. 1. Structures of itraconazole and hydroxyitraconazole. Candida albicans, Candida glabrata, Candida guilliermondii, Candida tropicalis,
More informationepidermidis, Enterococcus faecalis, Enterococcus Klebsiella pneumoniae, Proteus mirabilis, indolepositive Proteus spp., Enterobacter spp., Serratia
epidermidis, Enterococcus faecalis, Enterococcus Klebsiella pneumoniae, Proteus mirabilis, indolepositive Proteus spp., Enterobacter spp., Serratia Table 3. Overall clinical efficacy of cefozopran in
More information400 46 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 Dec. 2012 LVFX 100 mg 3 / 7 150 mg 2 / 7 2 2006 2008 9 LVFX PK PD 2009 7 100 mg 1 3 500 mg 1 1 AUC/MIC
Dec. 2012 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 399 45 2012 11 5 LVFX 500 mg 1 1 20 Chlamydia trachomatis C. trachomatismycoplasma genitalium M. genitalium LVFX 1 500 mg 1 1 7 22 22 C. trachomatis 17
More informationTable 1. Influence of urine ph on MBCs of new quinolones against Escherichia coli NIHJ JC-2 and Pseudomonas aeruginosa 18S; MBCs in urine were compared with those in Miieller-Hinton broth. Table 2. Influence
More informationCHEMOTHERAPY Table 2 Clinical response of 6059-S by infection Table 3 Effect of 6059-S on blood chemistry *Normal range : S-GOT 20 `60 mu/ml, S-GPT 5 `25 IU/L, Al-Pase 30 `85 mu/ml In oilier cases : S-GOT
More information明海大学歯学雑誌 37‐2/1.秦泉寺
J Meikai Dent Med 37, 153 158, 8 153 1 7 5ml /1 min Wong-Baker Face Rating Scale FS 5 1 9. g 3 5ml /1 min, FS 1 66 6ml /1 min FS 5 1 9. g 3 6ml /1 min, FS 3 Two Cases of Xerostomia that Showed an Improvement
More informationCHEMOTHERAPY
CHEMOTHERAPY CHEMOTHERAPY Table 1 Antibacterial activity of BRL 28500 against standard strains of bacteria Fig, 1 Sensitivity distribution of ABPC-resistant E. coli isolated from urinary tract Fig. 2 Sensitivity
More informationTable 1.Distribution and number of cases with acute upper respiratory tract infections classified according to antimicrobial agents administered Table 2. Distribution of cases which were enrolled to set
More information食道がん化学放射線療法後のsalvage手術
2006 2 17 52 Daly JM, et al. J Am Coll Surg 2000;190:562-573 Esophageal Cancer: Results of an American College of Surgeons Patient Care Evaluation Study Daly JM, et al. J Am Coll Surg 2000;190:562-573
More information